JP2010505931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505931A5 JP2010505931A5 JP2009531917A JP2009531917A JP2010505931A5 JP 2010505931 A5 JP2010505931 A5 JP 2010505931A5 JP 2009531917 A JP2009531917 A JP 2009531917A JP 2009531917 A JP2009531917 A JP 2009531917A JP 2010505931 A5 JP2010505931 A5 JP 2010505931A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- phenyl
- methanone
- isoindol
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 185
- 229910052739 hydrogen Inorganic materials 0.000 claims description 77
- 239000001257 hydrogen Substances 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 68
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 52
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- -1 NR c Inorganic materials 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 30
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 241000124008 Mammalia Species 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 125000002837 carbocyclic group Chemical group 0.000 claims description 24
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 23
- 239000011737 fluorine Substances 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 208000024891 symptom Diseases 0.000 claims description 19
- 230000002159 abnormal effect Effects 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 13
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 150000001204 N-oxides Chemical class 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- CCUXEBOOTMDSAM-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-(1-methylsulfonylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)C=NN1 CCUXEBOOTMDSAM-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- YYVAXCVMFDJHBF-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-methylpiperazin-1-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)N2CCN(C)CC2)=C1O YYVAXCVMFDJHBF-UHFFFAOYSA-N 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- RKWHYDXSPNNDBR-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-(3-morpholin-4-ylpropoxy)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(OCCCN4CCOCC4)C=CC=C3C2)=C1O RKWHYDXSPNNDBR-UHFFFAOYSA-N 0.000 claims description 4
- JVQQVJXMYAIHFT-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-hydroxy-1-methylpiperidin-4-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C2(O)CCN(C)CC2)=C1O JVQQVJXMYAIHFT-UHFFFAOYSA-N 0.000 claims description 4
- HIIKFACAQJEYEI-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(NC4CCN(C)CC4)=CC=C3C2)=C1O HIIKFACAQJEYEI-UHFFFAOYSA-N 0.000 claims description 4
- IMCANAAIYOYWDU-UHFFFAOYSA-N (5-chloro-2,4-dihydroxyphenyl)-[5-(4-methylpiperazin-1-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1CN(C)CCN1C1=CC=C(CN(C2)C(=O)C=3C(=CC(O)=C(Cl)C=3)O)C2=C1 IMCANAAIYOYWDU-UHFFFAOYSA-N 0.000 claims description 4
- CXBHMSHVCKEEGW-UHFFFAOYSA-N 4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 CXBHMSHVCKEEGW-UHFFFAOYSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 230000033077 cellular process Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- IFRGXKKQHBVPCQ-UHFFFAOYSA-N onalespib Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(CN4CCN(C)CC4)=CC=C3C2)=C1O IFRGXKKQHBVPCQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 230000029812 viral genome replication Effects 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- YCAYPVJEOCBCCR-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-piperazin-1-yl-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)N2CCNCC2)=C1O YCAYPVJEOCBCCR-UHFFFAOYSA-N 0.000 claims description 3
- JGSGWWWQXTYLGD-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(dimethylamino)methyl]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(CN(C)C)=CC=C3C2)=C1O JGSGWWWQXTYLGD-UHFFFAOYSA-N 0.000 claims description 3
- QVVRLPMMRCAKBP-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[2-(dimethylamino)ethoxy]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCN(C)C)=CC=C3C2)=C1O QVVRLPMMRCAKBP-UHFFFAOYSA-N 0.000 claims description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 3
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- SSZRLOSKSNZFFK-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(4-fluoro-1,3-dihydroisoindol-2-yl)methanone;hydrochloride Chemical compound Cl.C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(F)C=CC=C3C2)=C1O SSZRLOSKSNZFFK-UHFFFAOYSA-N 0.000 claims description 2
- KPWQHNKPRDITRE-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-fluoro-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(F)=CC=C3C2)=C1O KPWQHNKPRDITRE-UHFFFAOYSA-N 0.000 claims description 2
- CGDIZMUZKWJVOO-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-hydroxy-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(O)=CC=C3C2)=C1O CGDIZMUZKWJVOO-UHFFFAOYSA-N 0.000 claims description 2
- XGWIZXRDVRVZEK-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-methoxy-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1C2=CC(OC)=CC=C2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O XGWIZXRDVRVZEK-UHFFFAOYSA-N 0.000 claims description 2
- JUTGATVTVPQMEL-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-methyl-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(C)=CC=C3C2)=C1O JUTGATVTVPQMEL-UHFFFAOYSA-N 0.000 claims description 2
- LUCGOGCKXFESLJ-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(5-morpholin-4-yl-1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)N2CCOCC2)=C1O LUCGOGCKXFESLJ-UHFFFAOYSA-N 0.000 claims description 2
- BHIGZZZLNMKWKD-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-(4-methylpiperazin-1-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(N4CCN(C)CC4)C=CC=C3C2)=C1O BHIGZZZLNMKWKD-UHFFFAOYSA-N 0.000 claims description 2
- HHHYTVUIDNOPQP-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-(piperidin-4-ylamino)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(NC4CCNCC4)C=CC=C3C2)=C1O HHHYTVUIDNOPQP-UHFFFAOYSA-N 0.000 claims description 2
- HXJZVSQZQZCYGZ-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-[2-(2-methoxyethoxy)ethoxy]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1C=2C(OCCOCCOC)=CC=CC=2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O HXJZVSQZQZCYGZ-UHFFFAOYSA-N 0.000 claims description 2
- IVIKKSNFTPZPFF-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-[2-(dimethylamino)ethoxy]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(OCCN(C)C)C=CC=C3C2)=C1O IVIKKSNFTPZPFF-UHFFFAOYSA-N 0.000 claims description 2
- LYUXFHBOSWVIRE-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(2-methoxyethoxy)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1C2=CC(OCCOC)=CC=C2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O LYUXFHBOSWVIRE-UHFFFAOYSA-N 0.000 claims description 2
- AMUHXLKGSWMZEA-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(3-morpholin-4-ylpropoxy)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCCN4CCOCC4)=CC=C3C2)=C1O AMUHXLKGSWMZEA-UHFFFAOYSA-N 0.000 claims description 2
- SVHNLCFHSPNERJ-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-hydroxypiperidin-4-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C2(O)CCNCC2)=C1O SVHNLCFHSPNERJ-UHFFFAOYSA-N 0.000 claims description 2
- UONLQFDHEGREOV-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-morpholin-4-ylpiperidin-1-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)N2CCC(CC2)N2CCOCC2)=C1O UONLQFDHEGREOV-UHFFFAOYSA-N 0.000 claims description 2
- PEDLIUGWZBQXFP-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-piperazin-1-ylphenyl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C=2C=CC(=CC=2)N2CCNCC2)=C1O PEDLIUGWZBQXFP-UHFFFAOYSA-N 0.000 claims description 2
- MTRYSRYJRINGBV-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(4-propan-2-ylpiperazin-1-yl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1CN(C(C)C)CCN1C1=CC=C(CN(C2)C(=O)C=3C(=CC(O)=C(C(C)C)C=3)O)C2=C1 MTRYSRYJRINGBV-UHFFFAOYSA-N 0.000 claims description 2
- IBDJXXHTJPHOJQ-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(morpholin-4-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(CN4CCOCC4)=CC=C3C2)=C1O IBDJXXHTJPHOJQ-UHFFFAOYSA-N 0.000 claims description 2
- AFCDQRNSLCTCHH-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(piperidin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(CN4CCCCC4)=CC=C3C2)=C1O AFCDQRNSLCTCHH-UHFFFAOYSA-N 0.000 claims description 2
- ZSOPJQACGPRLBY-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-(piperidin-4-ylamino)-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(NC4CCNCC4)=CC=C3C2)=C1O ZSOPJQACGPRLBY-UHFFFAOYSA-N 0.000 claims description 2
- RKICJLSKDUSLPK-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[2-(2,2-dimethylpropylamino)ethoxy]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCNCC(C)(C)C)=CC=C3C2)=C1O RKICJLSKDUSLPK-UHFFFAOYSA-N 0.000 claims description 2
- RHYWLHRFSBDYOC-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[2-(propan-2-ylamino)ethoxy]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1C2=CC(OCCNC(C)C)=CC=C2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O RHYWLHRFSBDYOC-UHFFFAOYSA-N 0.000 claims description 2
- QHIUCJMWZIQBCV-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[4-(2-hydroxyethyl)piperazin-1-yl]-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)N2CCN(CCO)CC2)=C1O QHIUCJMWZIQBCV-UHFFFAOYSA-N 0.000 claims description 2
- IOBATCZTSZQFKE-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[6-[2-(dimethylamino)ethoxy]-4-methyl-1,3-dihydroisoindol-2-yl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(C)C=C(OCCN(C)C)C=C3C2)=C1O IOBATCZTSZQFKE-UHFFFAOYSA-N 0.000 claims description 2
- RDXRYKAWPOKHKF-UHFFFAOYSA-N (3-butan-2-yl-4-hydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)CC)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1 RDXRYKAWPOKHKF-UHFFFAOYSA-N 0.000 claims description 2
- AGHRSYDXIACWAH-UHFFFAOYSA-N (3-tert-butyl-4-hydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1 AGHRSYDXIACWAH-UHFFFAOYSA-N 0.000 claims description 2
- NRRDDJRMRDLCEE-UHFFFAOYSA-N (3-tert-butyl-4-hydroxyphenyl)-(2,3-dihydroindol-1-yl)methanone Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(=O)N2C3=CC=CC=C3CC2)=C1 NRRDDJRMRDLCEE-UHFFFAOYSA-N 0.000 claims description 2
- DOBRSHLMCIYEEI-UHFFFAOYSA-N (4,7-difluoro-1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=C(C(=CC=C3F)F)C2)=C1O DOBRSHLMCIYEEI-UHFFFAOYSA-N 0.000 claims description 2
- JGKVBQVQYZFVMN-UHFFFAOYSA-N (5-amino-1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(N)=CC=C3C2)=C1O JGKVBQVQYZFVMN-UHFFFAOYSA-N 0.000 claims description 2
- OTKZPCDLOLLPPV-UHFFFAOYSA-N (5-bromo-2,4-dihydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(Br)C(O)=CC(O)=C1C(=O)N1CC2=CC=CC=C2C1 OTKZPCDLOLLPPV-UHFFFAOYSA-N 0.000 claims description 2
- JUVRJNYFHAUUEF-UHFFFAOYSA-N (5-butan-2-yl-2,4-dihydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)CC)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1O JUVRJNYFHAUUEF-UHFFFAOYSA-N 0.000 claims description 2
- FBMKRVXJVXRCOJ-UHFFFAOYSA-N (5-chloro-1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(Cl)=CC=C3C2)=C1O FBMKRVXJVXRCOJ-UHFFFAOYSA-N 0.000 claims description 2
- ZGNOUNLCAKAXLK-UHFFFAOYSA-N (5-chloro-2,4-dihydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(Cl)C(O)=CC(O)=C1C(=O)N1CC2=CC=CC=C2C1 ZGNOUNLCAKAXLK-UHFFFAOYSA-N 0.000 claims description 2
- KJBMWHODWAFZCN-UHFFFAOYSA-N (5-chloro-2-hydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound OC1=CC=C(Cl)C=C1C(=O)N1CC2=CC=CC=C2C1 KJBMWHODWAFZCN-UHFFFAOYSA-N 0.000 claims description 2
- JQSCFWZZAQFLTE-UHFFFAOYSA-N (5-chloro-6-hydroxy-1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(Cl)=C(O)C=C3C2)=C1O JQSCFWZZAQFLTE-UHFFFAOYSA-N 0.000 claims description 2
- OUHQXCXLZQKCKS-UHFFFAOYSA-N (5-chloro-6-methoxy-1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1C=2C=C(Cl)C(OC)=CC=2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O OUHQXCXLZQKCKS-UHFFFAOYSA-N 0.000 claims description 2
- OHYDZLGYBUJAFY-UHFFFAOYSA-N (5-cyclopropyl-2,4-dihydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound OC1=CC(O)=C(C(=O)N2CC3=CC=CC=C3C2)C=C1C1CC1 OHYDZLGYBUJAFY-UHFFFAOYSA-N 0.000 claims description 2
- FUNJEJVGXFUOOI-UHFFFAOYSA-N (5-tert-butyl-2,4-dihydroxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1O FUNJEJVGXFUOOI-UHFFFAOYSA-N 0.000 claims description 2
- DPKGPEGXWFTAIR-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1O DPKGPEGXWFTAIR-UHFFFAOYSA-N 0.000 claims description 2
- FYANAIGOGAIFAF-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)N1CC2=CC=CC=C2C1 FYANAIGOGAIFAF-UHFFFAOYSA-N 0.000 claims description 2
- GVQMBIBELAOLRP-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(2-fluoro-4,6-dihydroxy-3-propan-2-ylphenyl)methanone Chemical compound CC(C)C1=C(O)C=C(O)C(C(=O)N2CC3=CC=CC=C3C2)=C1F GVQMBIBELAOLRP-UHFFFAOYSA-N 0.000 claims description 2
- RFBYLLKEEZKILL-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(2-hydroxy-4-methoxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(C(C)C)C(OC)=CC(O)=C1C(=O)N1CC2=CC=CC=C2C1 RFBYLLKEEZKILL-UHFFFAOYSA-N 0.000 claims description 2
- WDHZGMSZCVJKRF-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(3-fluoro-2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound FC1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1O WDHZGMSZCVJKRF-UHFFFAOYSA-N 0.000 claims description 2
- MEPNUQXOYQXDBH-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(4-hydroxy-3-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1 MEPNUQXOYQXDBH-UHFFFAOYSA-N 0.000 claims description 2
- LWKQBIRSZKDRSA-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-(5-ethyl-2,4-dihydroxyphenyl)methanone Chemical compound C1=C(O)C(CC)=CC(C(=O)N2CC3=CC=CC=C3C2)=C1O LWKQBIRSZKDRSA-UHFFFAOYSA-N 0.000 claims description 2
- IXKJNPYGWZPPIJ-UHFFFAOYSA-N 1,3-dihydroisoindol-2-yl-[2,4-dihydroxy-5-(trifluoromethyl)phenyl]methanone Chemical compound OC1=CC(O)=C(C(F)(F)F)C=C1C(=O)N1CC2=CC=CC=C2C1 IXKJNPYGWZPPIJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- SHSWHTFIEDMUJH-UHFFFAOYSA-N 2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindole-5-carboxylic acid Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C(O)=O)=C1O SHSWHTFIEDMUJH-UHFFFAOYSA-N 0.000 claims description 2
- UWANMJIXIZUGCE-UHFFFAOYSA-N 4-[(2,6-difluorobenzoyl)amino]-n-(1-methylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(F)C=CC=C1F UWANMJIXIZUGCE-UHFFFAOYSA-N 0.000 claims description 2
- NPPBDFFMJNUJRY-UHFFFAOYSA-N 4-[(2-fluoro-6-methoxybenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound COC1=CC=CC(F)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 NPPBDFFMJNUJRY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- VEXYXTFGBSZUKJ-UHFFFAOYSA-N [2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindol-5-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C(=O)N2CCN(C)CC2)=C1O VEXYXTFGBSZUKJ-UHFFFAOYSA-N 0.000 claims description 2
- VHHBLJSXWOIJGE-UHFFFAOYSA-N [2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindol-5-yl]-piperazin-1-ylmethanone;hydrochloride Chemical compound Cl.C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(=CC=C3C2)C(=O)N2CCNCC2)=C1O VHHBLJSXWOIJGE-UHFFFAOYSA-N 0.000 claims description 2
- AOPZUOIZRHXLCT-UHFFFAOYSA-N [5-(2-aminoethoxy)-1,3-dihydroisoindol-2-yl]-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCN)=CC=C3C2)=C1O AOPZUOIZRHXLCT-UHFFFAOYSA-N 0.000 claims description 2
- DNIWSQGPKWTEIU-UHFFFAOYSA-N [5-(3-aminopropoxy)-1,3-dihydroisoindol-2-yl]-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCCN)=CC=C3C2)=C1O DNIWSQGPKWTEIU-UHFFFAOYSA-N 0.000 claims description 2
- IVKPVAABBQNPCR-UHFFFAOYSA-N [5-[2-(cyclopentylamino)ethoxy]-1,3-dihydroisoindol-2-yl]-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCNC4CCCC4)=CC=C3C2)=C1O IVKPVAABBQNPCR-UHFFFAOYSA-N 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- WPAPDGACBUFALD-UHFFFAOYSA-N methyl 2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindole-5-carboxylate Chemical compound C1C2=CC(C(=O)OC)=CC=C2CN1C(=O)C1=CC(C(C)C)=C(O)C=C1O WPAPDGACBUFALD-UHFFFAOYSA-N 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- MCTUTCYGLQYYMC-UHFFFAOYSA-N tert-butyl 4-[[2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindol-5-yl]amino]piperidine-1-carboxylate Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(NC4CCN(CC4)C(=O)OC(C)(C)C)=CC=C3C2)=C1O MCTUTCYGLQYYMC-UHFFFAOYSA-N 0.000 claims description 2
- RLRUTAATUASFCD-UHFFFAOYSA-N tert-butyl n-[3-[[2-(2,4-dihydroxy-5-propan-2-ylbenzoyl)-1,3-dihydroisoindol-5-yl]oxy]propyl]carbamate Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(OCCCNC(=O)OC(C)(C)C)=CC=C3C2)=C1O RLRUTAATUASFCD-UHFFFAOYSA-N 0.000 claims description 2
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 206010043706 Thyroid cyst Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 description 26
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 15
- 229940116871 l-lactate Drugs 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 12
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 12
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 11
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 229950006191 gluconic acid Drugs 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FTAYVIUSDFIIQI-UHFFFAOYSA-N 2,6-dichloro-n-(1h-pyrazol-4-yl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1 FTAYVIUSDFIIQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- VBGAAXYBZSPNRF-UHFFFAOYSA-N n-(1-methylsulfonylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=NNC=C1 VBGAAXYBZSPNRF-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82919606P | 2006-10-12 | 2006-10-12 | |
| US60/829,196 | 2006-10-12 | ||
| PCT/GB2007/003879 WO2008044041A1 (en) | 2006-10-12 | 2007-10-12 | Pharmaceutical combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505931A JP2010505931A (ja) | 2010-02-25 |
| JP2010505931A5 true JP2010505931A5 (enExample) | 2011-12-15 |
| JP5528806B2 JP5528806B2 (ja) | 2014-06-25 |
Family
ID=39135283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531917A Expired - Fee Related JP5528806B2 (ja) | 2006-10-12 | 2007-10-12 | 複合薬剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8916552B2 (enExample) |
| EP (1) | EP2073803B1 (enExample) |
| JP (1) | JP5528806B2 (enExample) |
| WO (1) | WO2008044041A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| CN101193862B (zh) | 2005-04-13 | 2013-08-21 | 阿斯特克斯治疗有限公司 | 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5518478B2 (ja) * | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| AU2008354754B2 (en) * | 2008-04-17 | 2014-09-11 | The Johns Hopkins University | On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors |
| GB201009853D0 (en) * | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| WO2012088305A1 (en) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
| EP2721042A4 (en) * | 2011-06-14 | 2015-03-18 | Hetero Research Foundation | NEW POLYMORPHS OF FOSAMPRENAVIR CALCIUM |
| EP3072964A1 (en) * | 2013-11-22 | 2016-09-28 | National Center For Child Health And Development | Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3261628A4 (en) * | 2015-02-24 | 2018-10-31 | King Abdullah University Of Science And Technology | Cholesteryl ester transfer protein (cetp) inhibition in the treatment of cancer |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| WO2017091762A1 (en) * | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019027203A1 (ko) * | 2017-08-02 | 2019-02-07 | 계명대학교 산학협력단 | Ｈｓｐ９０ 억제 활성을 갖는 디히드록시페닐계 입체이성질체 및 이의 의학적 용도 |
| CN110690462B (zh) * | 2019-10-13 | 2020-10-23 | 浙江大学 | 具有锂离子传导能力的自支撑正极的制备及应用方法 |
Family Cites Families (242)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US2512572A (en) | 1950-06-20 | Substituted pteridines and method | ||
| GB620259A (en) | 1946-03-12 | 1949-03-22 | Robert Rufus Carver | Churns |
| US2917432A (en) | 1954-10-05 | 1959-12-15 | Burroughs Wellcome Co | Leukemia treatment |
| US2848455A (en) | 1955-07-18 | 1958-08-19 | Ciba Pharm Prod Inc | Alpha-(p-amino-phenyl)-alpha-lower alkyl glutarimides |
| US2891079A (en) | 1959-01-23 | 1959-06-16 | Searle & Co | 6-methyl-4, 6-pregnadiene-3, 20-dione and 17alpha-acyloxy derivatives thereof |
| US3046301A (en) | 1959-10-29 | 1962-07-24 | Burroughs Wellcome Co | Method of making chlorambucil |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| BE637389A (enExample) | 1962-09-13 | |||
| US3432549A (en) | 1965-04-22 | 1969-03-11 | Egyt Gyogyszervegyeszeti Gyar | Pharmacologically active new substituted benzamides |
| US3732340A (en) | 1966-07-11 | 1973-05-08 | Asta Werke Ag Chem Fab | N',o-propylene phosphoric acid ester diamides |
| US3803124A (en) | 1968-04-12 | 1974-04-09 | Farmaceutici It Soc | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives |
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| GB1235022A (en) | 1969-06-04 | 1971-06-09 | Laeaeke Ag | A new method for the production of cyclophosphamide |
| CH526500A (de) | 1969-12-31 | 1972-08-15 | Hoffmann La Roche | Verfahren zur Herstellung von Polyenverbindungen |
| DE2124023C3 (de) | 1970-05-27 | 1980-07-10 | Richter Gedeon Vegyeszeti Gyar R.T., Budapest | Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten |
| JPS4910506Y1 (enExample) | 1970-10-20 | 1974-03-13 | ||
| GB1354939A (en) | 1971-10-28 | 1974-06-05 | Ici Ltd | Process for the manufacture of 1,1,2-triphenylalk-1-enes |
| CH605550A5 (enExample) | 1972-06-08 | 1978-09-29 | Research Corp | |
| AR204004A1 (es) | 1973-04-02 | 1975-11-12 | Lilly Co Eli | Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina |
| US3914412A (en) | 1973-10-11 | 1975-10-21 | Abbott Lab | {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity |
| US4005063A (en) | 1973-10-11 | 1977-01-25 | Abbott Laboratories | [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity |
| GB1457632A (en) | 1974-03-22 | 1976-12-08 | Farmaceutici Italia | Adriamycins |
| US4020270A (en) | 1974-05-02 | 1977-04-26 | Societa' Farmaceutici Italia S.P.A. | L-lyxohex-1-enopyranose derivative |
| GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
| DE2438350C3 (de) | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4197249A (en) | 1977-08-15 | 1980-04-08 | American Cyanamid Company | 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof |
| US4307100A (en) | 1978-08-24 | 1981-12-22 | Agence Nationale De Valorisation De La Recherche (Anvar) | Nor bis-indole compounds usable as medicaments |
| DE2845574A1 (de) | 1978-10-19 | 1980-04-24 | Deutsches Krebsforsch | Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| EP0111058B1 (en) | 1982-11-26 | 1987-11-04 | Nippon Kayaku Kabushiki Kaisha | Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4691918A (en) | 1985-10-08 | 1987-09-08 | Diversified Products Corporation | Multiple exercise device |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| JPS62220196A (ja) | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ｕｃｎ―０１ |
| IN164232B (enExample) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| NZ224714A (en) | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
| GB8714013D0 (en) | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| CA1340191C (en) | 1988-06-13 | 1998-12-15 | Katsuhiro Imaki | Derivatives of p-substituted phenyl ester of pivalic acid |
| US4990511A (en) | 1988-08-03 | 1991-02-05 | Takeda Chemical Industries, Ltd. | Amide compounds, their production and use |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| IL96531A (en) | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
| US5124350A (en) * | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| CA2049481A1 (en) | 1990-08-27 | 1992-02-28 | Jill Ann Panetta | Method of treating inflammatory bowel disease |
| TW295589B (enExample) | 1990-08-30 | 1997-01-11 | Hoechst Ag | |
| FR2669029B1 (fr) | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US5280046A (en) | 1991-02-22 | 1994-01-18 | The University Of Colorado Foundation, Inc. | Method of treating type I diabetes |
| WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
| GB9112859D0 (en) | 1991-06-14 | 1991-07-31 | Ici Plc | Peptide process |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| IT1250692B (it) | 1991-07-23 | 1995-04-21 | Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi. | |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| DE69333894D1 (de) | 1992-04-22 | 2005-12-01 | Ligand Pharm Inc | Verbindungen mit Retinoid x rezeptorselektivität |
| DE4222910A1 (de) | 1992-07-11 | 1994-01-13 | Asta Medica Ag | Neue Phospholipidderivate |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5466861A (en) | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2277954A1 (en) | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5476932A (en) | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5633283A (en) | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| JPH0910506A (ja) | 1995-06-30 | 1997-01-14 | Toshiba Corp | 脱気器 |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| JP3855026B2 (ja) | 1996-01-16 | 2006-12-06 | 富士レビオ株式会社 | アミド誘導体の製造方法 |
| ATE478672T1 (de) | 1996-01-29 | 2010-09-15 | Univ California | Methode zur behandlung sexueller fehlfunktionen |
| GB9606187D0 (en) | 1996-03-23 | 1996-05-29 | Inst Of Food Research | Production of vanillin |
| CA2249615A1 (en) | 1996-04-03 | 1997-10-09 | Robert Gomez | Inhibitors of farnesyl-protein transferase |
| EP0918518A4 (en) | 1996-04-19 | 2002-05-02 | Univ California | TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS. |
| IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
| DE69728986T2 (de) | 1996-06-21 | 2005-04-07 | Allergan, Inc., Irvine | Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| GB9719426D0 (en) | 1997-09-13 | 1997-11-12 | Johnson Matthey Plc | Novel process |
| US6166008A (en) | 1997-10-27 | 2000-12-26 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1165492A1 (en) | 1999-03-30 | 2002-01-02 | Pharmacor Inc. | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US6166244A (en) | 1999-05-07 | 2000-12-26 | Allergan Sales, Inc. | Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity |
| US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| EP1226129B1 (en) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| DE19955283A1 (de) | 1999-11-17 | 2001-05-23 | Aventis Res & Tech Gmbh & Co | Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| AU2001243158A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2001240658A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| US6613917B1 (en) | 2000-03-23 | 2003-09-02 | Allergan, Inc. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| JP2004507456A (ja) * | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| DE10024939A1 (de) | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| BR0111754A (pt) | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| CA2413134C (en) | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| AP2001002249A0 (en) | 2000-08-25 | 2001-09-30 | Warner Lambert Co | Process for making N-ARYL-ANTHRANILIC acids and their derivatives. |
| BRPI0113757B8 (pt) | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| WO2002036574A1 (en) | 2000-11-06 | 2002-05-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Geldanamycin derivatives useful for the treatment of cancer |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| WO2002049632A1 (en) | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| NZ526624A (en) | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| CA2440809A1 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| EP1420747A4 (en) | 2001-08-06 | 2010-06-02 | Kosan Biosciences Inc | ANSAMYCIN BENZOQUINONE |
| JP2005504086A (ja) | 2001-09-24 | 2005-02-10 | コンフォーマ セラピューティクス コーポレーション | １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法 |
| AU2002366362A1 (en) | 2001-12-18 | 2003-06-30 | Bayer Aktiengesellschaft | 2-substituted pyrrolo(2.1-a)isoquinolines against cancer |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| SE0104462D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Peptide purifcation (Peptidrening) |
| WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| EP1497268A4 (en) | 2002-04-05 | 2006-01-18 | Nitromed Inc | NITROGEN OXIDE DISPENSER, COMPOSITIONS AND METHOD OF USE |
| AU2003224341A1 (en) | 2002-04-26 | 2003-11-10 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| EA009523B1 (ru) * | 2002-06-05 | 2008-02-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Ингибиторы в отношении активации ар-1 и nfat |
| CA2488342A1 (en) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Therapeutic drug for diabetes |
| WO2003103658A1 (ja) | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | 免疫関連プロテインキナーゼ阻害剤 |
| AU2003242103A1 (en) * | 2002-06-06 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc | Antiallergic agents |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| CN100354276C (zh) | 2002-07-16 | 2007-12-12 | 阿姆拉医疗有限公司 | 生物活性化合物 |
| US6800655B2 (en) | 2002-08-20 | 2004-10-05 | Sri International | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents |
| JP2006505571A (ja) | 2002-10-15 | 2006-02-16 | リゲル ファーマシューテイカルズ、インコーポレイテッド | 置換されたインドール及びｈｃｖ阻害剤としてのその使用 |
| AU2003302589A1 (en) | 2002-12-02 | 2004-06-23 | Kyukyu Pharmaceutical Co., Ltd. | Method for producing orally administrable edible agent of laminate film form and pressure bonding apparatus of the agent. |
| TWI228885B (en) * | 2003-01-23 | 2005-03-01 | Mediatek Inc | Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode |
| KR101166749B1 (ko) | 2003-02-11 | 2012-07-27 | 베르날리스(캠브리지)리미티드 | 열쇼크 단백질 저해제로서의 이소옥사졸 화합물 |
| JP2006514088A (ja) * | 2003-02-20 | 2006-04-27 | ユニバーシティー オブ コネティカット ヘルス センター | 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法 |
| JP2006518368A (ja) | 2003-02-21 | 2006-08-10 | ファイザー・インク | プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体 |
| DE50307267D1 (de) | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| KR20050119671A (ko) | 2003-04-03 | 2005-12-21 | 화이자 인코포레이티드 | Ａｇ013736을 포함하는 제형 |
| AU2004234067B2 (en) | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| AU2004251949B2 (en) | 2003-06-27 | 2009-05-07 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
| TWI322806B (en) | 2003-06-30 | 2010-04-01 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US6989649B2 (en) * | 2003-07-09 | 2006-01-24 | A. O. Smith Corporation | Switch assembly, electric machine having the switch assembly, and method of controlling the same |
| US20070042997A1 (en) * | 2003-07-16 | 2007-02-22 | Akiko Itai | Medicament for treatment of dermal pigmentation |
| EP2256106B1 (en) * | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| RU2396250C2 (ru) | 2003-07-24 | 2010-08-10 | Лео Фарма А/С | Новые производные аминобензофенона |
| WO2005012296A1 (en) | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| DE10335584B4 (de) * | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Verfahren zur Herstellung zyklischer Moleküle |
| DE10335726A1 (de) * | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
| WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| JP4823914B2 (ja) | 2003-11-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｆｇｆｒ３の阻害および多発性骨髄腫の治療 |
| CN1902171A (zh) | 2003-11-10 | 2007-01-24 | 舍林股份公司 | 用作ccr－5拮抗剂的苄醚胺化合物 |
| SI1686997T1 (sl) | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| US7282493B2 (en) | 2003-12-23 | 2007-10-16 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| EP1704856A4 (en) | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
| US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| TWI338004B (en) | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20050256097A1 (en) | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| KR101792651B1 (ko) | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| US7351709B2 (en) * | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060067953A1 (en) | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| US7208630B2 (en) * | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| WO2006050333A2 (en) | 2004-11-02 | 2006-05-11 | The Regents Of The University Of California | Methods and compositions for modulating apoptosis |
| BRPI0517921A (pt) | 2004-11-02 | 2008-10-21 | Pfizer | métodos para preparar compostos de indazol |
| CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| US7781485B2 (en) * | 2004-11-09 | 2010-08-24 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| MX2007008008A (es) | 2004-12-30 | 2007-11-12 | Astex Therapeutics Ltd | Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora. |
| US7687473B2 (en) | 2005-01-07 | 2010-03-30 | Health Research, Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
| AR052559A1 (es) | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| WO2006082001A1 (en) * | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1 |
| WO2006088954A1 (en) * | 2005-02-15 | 2006-08-24 | Janssen Pharmaceutica, N.V. | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| JPWO2006088193A1 (ja) | 2005-02-21 | 2008-07-03 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
| CN101193862B (zh) * | 2005-04-13 | 2013-08-21 | 阿斯特克斯治疗有限公司 | 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途 |
| JP2008540395A (ja) * | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| US7754725B2 (en) * | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5721949B2 (ja) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
| US20090019958A1 (en) * | 2007-07-20 | 2009-01-22 | Craig Howard Zeyher | Planetary gyroscopic drive system with transmission |
-
2007
- 2007-10-12 US US12/445,180 patent/US8916552B2/en not_active Expired - Fee Related
- 2007-10-12 WO PCT/GB2007/003879 patent/WO2008044041A1/en not_active Ceased
- 2007-10-12 JP JP2009531917A patent/JP5528806B2/ja not_active Expired - Fee Related
- 2007-10-12 EP EP07824133.8A patent/EP2073803B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505932A5 (enExample) | ||
| JP2010505928A5 (enExample) | ||
| CN109970708B (zh) | 大麻素受体调节剂 | |
| AU2017276457B2 (en) | Novel heterocyclic derivatives useful as SHP2 inhibitors | |
| US20100173954A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| ES2402469T3 (es) | Derivados de hidroxibenzamida y sus usos como inhibidores de la Hsp90 | |
| JP5528806B2 (ja) | 複合薬剤 | |
| JP2010505933A5 (enExample) | ||
| US8716287B2 (en) | Pharmaceutical compounds | |
| JP2008537751A5 (enExample) | ||
| RU2007131101A (ru) | Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований | |
| JP2023536164A5 (enExample) | ||
| JP2023545274A (ja) | 癌を処置する化合物および方法 | |
| AU2015213679A1 (en) | Pharmaceutical compounds | |
| BR112017026392B1 (pt) | Composto derivado tricíclico, método para sua preparação e seu uso | |
| TWI780061B (zh) | 吲哚啉酮化合物之用途 | |
| JP2013532727A5 (enExample) | ||
| WO2022051569A1 (en) | Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions | |
| AU2015290007B2 (en) | Fused quinoline compunds as pi3k, mTor inhibitors | |
| JP2015529194A5 (enExample) | ||
| JP2022500428A5 (enExample) | ||
| TW202045174A (zh) | 組合醫藥 | |
| JP2024542248A5 (enExample) | ||
| CN114790207B (zh) | 作为pi3k/mtor抑制剂的被取代的吡啶基取代的稠合喹啉化合物 | |
| WO2007059155A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents |